Table of Contents

    Topic review

    Potential of Brown Algae

    Subjects: Plant Sciences
    View times: 13


    Brown algae have been part of the human diet for hundreds of years, however, in recent years, commercial and scientific interest in brown algae has increased due to the growing demand for healthier diet by the world population. Brown algae and its metabolites, such as carotenoids, polysaccharides, phlorotannins, and proteins, have been associated with multiple beneficial health effects for different diseases, such as cardiovascular diseases, one of the main causes of death in Europe.

    1. Introduction

    Seaweeds are macroalgae used in different sectors, such as agricultural, horticultural, cosmetics, and food industries. It has been recognized that the novel and potentially bioactive components that algae present make them a good source of healthy food[1][2] World seaweed production doubled between 2005 and 2015. Globally, in 2016, seaweed products were valued at USD 10.6 million, and it is estimated that in 2025 the value of global seaweed products will reach USD 26 million[3]. Asia and the Pacific region dominate 60% of the world algae market, followed by Europe and the Americas[3]. Seaweeds have been used as part of the human diet for thousands of years. Archaeological evidence shows that in Chile it has been used for the last 14,000 years[1], and in Japan and China, there are written records describing the use of seaweed that date back over 2000 years[4][5]. Nowadays, in Europe, seaweed consumption is increasing, not only because people are becoming interested in the uses of natural products, but also because it is seen as a healthy and nutritious “superfood”, which is sold preserved dry, fresh, frozen, canned, or salted[3][6]. Algae are used both as a food supplement and as an addition to functional food. Meat products, cereal-based products, and fermented functional foods, such as cheeses, are the main products in the market supplemented with algae[7]. Statistics from the 2012 global harvest demonstrated that 38% of the 23.8 million seaweed harvest was used for human consumption, without counting the consumption of hydrocolloids derived from algae as agars, alginates, and carrageenans[1][8]. Currently, more than 10,000 species of algae are known, but only about 200 species are consumed worldwide, with the brown algae species being the most consumed, followed by red algae species and then the green algae species[6][9]. Despite the considerable number of brown algae species consumed worldwide, under the European regulation there are only about 23 brown seaweed species authorized for food applications.

    Table 1. List of brown algae species for human food applications in Europe under the regulation (UE) 2015/2283 [10].

    Brown Algae Species
    Ascophyllum nodosum
    Alaria esculenta
    Eisenia bicyclis
    Fucus vesiculosus
    Fucus serratus
    Fucus spiralis
    Himanthalia elongata
    Laminaria digitata
    Saccharina japonica
    Saccharina latissima
    Saccharina longicruris
    Sargassum fusiforme
    Undaria pinnatifida

    The entry is from 10.3390/foods10020234


    1. Wells, M.L.; Potin, P.; Craigie, J.S.; Raven, J.A.; Merchant, S.S.; Helliwell, K.E.; Smith, A.G.; Camire, M.E.; Brawley, S.H. Algae as nutritional and functional food sources: Revisiting our understanding. J. Appl. Phycol. 2017, 29, 949–982.
    2. Tanna, B.; Mishra, A. Nutraceutical Potential of Seaweed Polysaccharides: Structure, Bioactivity, Safety, and Toxicity. Compr. Rev. Food Sci. Food Saf. 2019, 18, 817–831.
    3. Ferdouse, F.; Holdt, S.L.; Smith, R.; Murúa, P.; Yang, Z. The Global Satus of Seaweed Production, Trade and Utilization; FAO: Rome, Italy, 2018; Volume 124.
    4. El Gamal, A.A. Biological importance of marine algae. Saudi Pharm. J. 2010, 18, 1–25.
    5. Xia, B.; Abbott, I.A. Edible Seaweeds of China and Their Place in the Chinese Diet. Econ. Bot. 1987, 41, 341–353.
    6. Mac Monagail, M.; Cornish, L.; Morrison, L.; Araújo, R.; Critchley, A.T. Sustainable harvesting of wild seaweed resources. Eur. J. Phycol. 2017, 52, 371–390.
    7. Ścieszka, S.; Klewicka, E. Algae in food: A general review. Crit. Rev. Food Sci. Nutr. 2019, 59, 3538–3547.
    8. FAO. The State of the World Fisheries and Aquaculture 2014; FAO: Rome, Italy, 2014.
    9. Lorenzo, J.; Agregán, R.; Munekata, P.; Franco, D.; Carballo, J.; Şahin, S.; Lacomba, R.; Barba, F. Proximate Composition and Nutritional Value of Three Macroalgae: Ascophyllum nodosum, Fucus vesiculosus and Bifurcaria bifurcata. Mar. Drugs 2017, 15, 360.
    10. Edible seaweed and microalgae—Regulatory status in France and Europe—2019 update. Available online: (accessed on 28 July 2020).
    11. Ganesan, A.R.; Tiwari, U.; Rajauria, G. Seaweed nutraceuticals and their therapeutic role in disease prevention. Food Sci. Hum. Wellness 2019, 8, 252–263.
    12. Catarino, M.; Silva, A.; Cardoso, S. Phycochemical Constituents and Biological Activities of Fucus spp. Mar. Drugs 2018, 16, 249.
    13. Yoon, N.Y.; Kim, H.R.; Chung, H.Y.; Choi, J.S. Anti-hyperlipidemic effect of an edible brown algae, Ecklonia stolonifera, and its constituents on poloxamer 407-induced hyperlipidemic and cholesterol-fed rats. Arch. Pharm. Res. 2008, 31, 1564–1571.
    14. Neto, R.; Marçal, C.; Queirós, A.; Abreu, H.; Silva, A.; Cardoso, S. Screening of Ulva rigida, Gracilaria sp., Fucus vesiculosus and Saccharina latissima as Functional Ingredients. Int. J. Mol. Sci. 2018, 19, 2987.
    15. Yamamoto, H.; Yamanashi, Y.; Takada, T.; Mu, S.; Tanaka, Y.; Komine, T.; Suzuki, H. Hepatic expression of Niemann-Pick C1-like 1, a cholesterol reabsorber from bile, exacerbates western diet-induced atherosclerosis in LDL receptor mutant mice S. Mol. Pharmacol. 2019, 96, 47–55.
    16. Li, R.; Liu, Y.; Shi, J.; Yu, Y.; Lu, H.; Yu, L.; Liu, Y.; Zhang, F. Diosgenin regulates cholesterol metabolism in hypercholesterolemic rats by inhibiting NPC1L1 and enhancing ABCG5 and ABCG8. Biochim. Biophys. Acta-Mol. Cell Biol. Lipids 2019, 1864, 1124–1133.
    17. Stone, N.J.; Robinson, J.G.; Lichtenstein, A.H.; Bairey Merz, C.N.; Blum, C.B.; Eckel, R.H.; Goldberg, A.C.; Gordon, D.; Levy, D.; Lloyd-Jones, D.M.; et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation 2014, 129, S1–S45.
    18. Choi, E.K.; Park, S.H.; Ha, K.C.; Noh, S.O.; Jung, S.J.; Chae, H.J.; Chae, S.W.; Park, T.S. Clinical trial of the hypolipidemic effects of a brown alga Ecklonia cava extract in patients with hypercholesterolemia. Int. J. Pharmacol. 2015, 11, 798–805.
    19. Sahoo, D.; Seckbach, J. (Eds.) The Algae World, 1st ed.; Springer: Dordrecht, The Netherlands, 2015; ISBN 9789401773201.
    20. Ge, L.; Wang, J.; Qi, W.; Miao, H.-H.; Cao, J.; Qu, Y.-X.; Li, B.-L.; Song, B.-L. The Cholesterol Absorption Inhibitor Ezetimibe Acts by Blocking the Sterol-Induced Internalization of NPC1L1. Cell Metab. 2008, 7, 508–519.
    21. Axmann, M.; Strobl, W.M.; Plochberger, B.; Stangl, H. Cholesterol transfer at the plasma membrane. Atherosclerosis 2019, 290, 111–117.
    22. Altmann, S.W.; Davis, H.R.; Zhu, L.J.; Yao, X.; Hoos, L.M.; Tetzloff, G.; Iyer, S.P.N.; Maguire, M.; Golovko, A.; Zeng, M.; et al. Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption. Science 2004, 303, 1201–1204.
    23. Espinheira, M.C.; Vasconcelos, C.; Medeiros, A.M.; Alves, A.C.; Bourbon, M.; Guerra, A. Hipercolesterolemia—Uma patologia com expressão desde a idade pediátrica. Rev. Port. Cardiol. 2013, 32, 379–386.
    24. White, C.R.; Anantharamaiah, G.M.; Datta, G. HDL mimetic peptides: Novel therapeutic strategies for the treatment of inflammatory vascular disease. In The HDL Handbook; Elsevier Inc.: Philadelphia, PA, USA, 2010; pp. 179–197. ISBN 9780123821713.
    25. Marques, L.R.; Diniz, T.A.; Antunes, B.M.; Rossi, F.E.; Caperuto, E.C.; Lira, F.S.; Gonçalves, D.C. Reverse cholesterol transport: Molecular mechanisms and the non-medical approach to enhance HDL cholesterol. Front. Physiol. 2018, 9, 526.
    26. Chistiakov, D.A.; Bobryshev, Y.V.; Orekhov, A.N. Macrophage-mediated cholesterol handling in atherosclerosis. J. Cell. Mol. Med. 2016, 20, 17–28.
    27. Yin, J.; Wang, J.; Li, F.; Yang, Z.; Yang, X.; Sun, W.; Xia, B.; Li, T.; Song, W.; Guo, S. The fucoidan from the brown seaweed: Ascophyllum nodosum ameliorates atherosclerosis in apolipoprotein E-deficient mice. Food Funct. 2019, 10, 5124–5139.
    28. Song, G.; Zong, C.; Liu, Q.; Si, Y.; Liu, J.; Li, W.; Zhu, P.; Qin, S. SR-BI associates with ABCG1 and inhibits ABCG1-mediated cholesterol efflux from cells to high-density lipoprotein 3. Lipids Health Dis. 2012, 11, 118.
    29. Dikkers, A.; Tietge, U.J.F. Biliary cholesterol secretion: More than a simple ABC. World J. Gastroenterol. 2010, 16, 5936–5945.
    30. Post, S.M.; De Crom, R.; Van Haperen, R.; Van Tol, A.; Princen, H.M.G. Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 892–897.
    31. Bosner, M.S.; Lange, L.G.; Stenson, W.F.; Ostlund, R.E. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J. Lipid Res. 1999, 40, 302–308.
    32. Betters, J.L.; Yu, L. NPC1L1 and cholesterol transport. FEBS Lett. 2010, 584, 2740–2747.
    33. Jia, L.; Betters, J.L.; Yu, L. Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport. Annu. Rev. Physiol. 2011, 73, 239–259.
    34. Yassine, H.N.; Belopolskaya, A.; Schall, C.; Stump, C.S.; Lau, S.S.; Reaven, P.D. Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. Metabolism 2014, 63, 727–734.
    35. Hui, D.Y.; Howles, P.N. Molecular mechanisms of cholesterol absorption and transport in the intestine. Semin. Cell Dev. Biol. 2005, 16, 183–192.
    36. Istvan, E. Statin inhibition of HMG-CoA reductase: A 3-dimensional view. Atheroscler. Suppl. 2003, 4, 3–8.
    37. Feingold, K.R. Cholesterol Lowering Drugs. In Endotext [Internet]; Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., Dungan, K., Grossman, A., Hershman, J.M., Kaltsas, G., Koch, C., Kopp, P., et al., Eds.;, Inc.: South Dartmouth, MA, USA, 2020.
    38. Ono, K. Current concept of reverse cholesterol transport and novel strategy for atheroprotection. J. Cardiol. 2012, 60, 339–343.
    39. Chapman, M. Are the effects of statins on HDL-cholesterol clinically relevant? Eur. Hear. J. Suppl. 2004, 6, C58–C63.
    40. Maejima, T.; Yamazaki, H.; Aoki, T.; Tamaki, T.; Sato, F.; Kitahara, M.; Saito, Y. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem. Biophys. Res. Commun. 2004, 324, 835–839.
    41. Xie, P.; Zhu, H.; Jia, L.; Ma, Y.; Tang, W.; Wang, Y.; Xue, B.; Shi, H.; Yu, L. Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels. Atherosclerosis 2014, 237, 609–617.
    42. Zhan, S.; Xia, P.; Tang, M.; Liu, F.; Shu, M.; Wu, X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst. Rev. 2017, 2017.
    43. Jaiganesh, R.; Sampath Kumar, N.S. Marine Bacterial Sources of Bioactive Compounds. Adv. Food Nutr. Res. 2012, 65, 389–408.
    44. Ji, S.Q.; Wang, B.; Lu, M.; Li, F.L. Direct bioconversion of brown algae into ethanol by thermophilic bacterium Defluviitalea phaphyphila. Biotechnol. Biofuels 2016, 9, 1–10.
    45. Wehr, J.D. Chapter 19—Brown Algae. In Freshwater Algae of North America; Wehr, J.D., Sheath, R.G., Kociolek, J.P., Eds.; Elsevier: Boston, MA, USA, 2015; pp. 851–871. ISBN 978-0-12-385876-4.
    46. Petruzzello, M. Brown Algae. Available online: (accessed on 28 July 2020).
    47. Sheath, R.G.; Wehr, J.D. Introduction to the Freshwater Algae. In Freshwater Algae of North America; Elsevier: Amsterdam, The Netherlands, 2015; pp. 1–11. ISBN 9780123858771.
    48. Díaz-Rubio, M.E.; Pérez-Jiménez, J.; Saura-Calixto, F. Dietary fiber and antioxidant capacity in Fucus vesiculosus products. Int. J. Food Sci. Nutr. 2009, 60, 23–34.
    49. Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer’s disease: Current status and new perspectives. Lancet Neurol. 2003, 2, 539–547.
    50. Rajauria, G.; Foley, B.; Abu-Ghannam, N. Identification and characterization of phenolic antioxidant compounds from brown Irish seaweed Himanthalia elongata using LC-DAD–ESI-MS/MS. Innov. Food Sci. Emerg. Technol. 2016, 37, 261–268.
    51. Afonso, N.C.; Catarino, M.D.; Silva, A.M.S.; Cardoso, S.M. Brown Macroalgae as Valuable Food Ingredients. Antioxidants 2019, 8, 365.
    52. Lee, D.H.; Park, M.Y.; Shim, B.J.; Youn, H.J.; Hwang, H.J.; Shin, H.C.; Jeon, H.K. Effects of Ecklonia cava Polyphenol in Individuals with Hypercholesterolemia: A Pilot Study. J. Med. Food 2012, 15, 1038–1044.
    53. Ara, J.; Sultana, V.; Qasim, R.; Ahmad, V.U. Hypolipidaemic activity of seaweed from Karachi coast. Phyther. Res. 2002, 16, 479–483.
    54. Olivares-Bañuelos, T.; Gutiérrez-Rodríguez, A.; Méndez-Bellido, R.; Tovar-Miranda, R.; Arroyo-Helguera, O.; Juárez-Portilla, C.; Meza-Menchaca, T.; Aguilar-Rosas, L.; Hernández-Kelly, L.; Ortega, A.; et al. Brown Seaweed Egregia menziesii’s Cytotoxic Activity against Brain Cancer Cell Lines. Molecules 2019, 24, 260.
    55. Miyashita, K.; Beppu, F.; Hosokawa, M.; Liu, X.; Wang, S. Nutraceutical characteristics of the brown seaweed carotenoid fucoxanthin. Arch. Biochem. Biophys. 2020, 686, 108364.
    56. Lin, H.-T.; Tsou, Y.-C.; Chen, Y.-T.; Lu, W.-J.; Hwang, P.-A. Effects of Low-Molecular-Weight Fucoidan and High Stability Fucoxanthin on Glucose Homeostasis, Lipid Metabolism, and Liver Function in a Mouse Model of Type II Diabetes. Mar. Drugs 2017, 15, 113.
    57. Gunathilaka, T.L.; Samarakoon, K.; Ranasinghe, P.; Peiris, L.D.C. Antidiabetic Potential of Marine Brown Algae—A Mini Review. J. Diabetes Res. 2020, 2020, 1–13.
    58. Krylova, N.V.; Ermakova, S.P.; Lavrov, V.F.; Leneva, I.A.; Kompanets, G.G.; Iunikhina, O.V.; Nosik, M.N.; Ebralidze, L.K.; Falynskova, I.N.; Silchenko, A.S.; et al. The Comparative Analysis of Antiviral Activity of Native and Modified Fucoidans from Brown Algae Fucus evanescens In Vitro and In Vivo. Mar. Drugs 2020, 18, 224.
    59. Xu, Y.; Xu, J.; Ge, K.; Tian, Q.; Zhao, P.; Guo, Y. Anti-inflammatory effect of low molecular weight fucoidan from Saccharina japonica on atherosclerosis in apoE-knockout mice. Int. J. Biol. Macromol. 2018, 118, 365–374.
    60. Dong, X.; Bai, Y.; Xu, Z.; Shi, Y.; Sun, Y.; Janaswamy, S.; Yu, C.; Qi, H. Phlorotannins from Undaria pinnatifida Sporophyll: Extraction, Antioxidant, and Anti-Inflammatory Activities. Mar. Drugs 2019, 17, 434.
    61. Ara, J.; Sultana, V.; Qasim, R.; Ehteshamul-Haque, S.; Ahmad, V.U. Biological activity of Spatoglossum asperum: A brown alga. Phyther. Res. 2005, 19, 618–623.
    62. Ren, D.; Noda, H.; Amano, H.; Nishino, T.; Nishizawa, K. Study on Antihypertensive and Antihyperlipidemic Effects of Marine Algae. Fish. Sci. 1994, 60, 83–88.
    63. Matanjun, P.; Mohamed, S.; Muhammad, K.; Mustapha, N.M. Comparison of Cardiovascular Protective Effects of Tropical Seaweeds, Kappaphycus alvarezii, Caulerpa lentillifera, and Sargassum polycystum, on High-Cholesterol/High-Fat Diet in Rats. J. Med. Food 2010, 13, 792–800.
    64. Wang, W.; Yoshie, Y.; Suzuki, T. Effect of small particle size of seaweeds on digestibility and lipid metabolism in rats. Nippon Suisan Gakkaishi 2002, 68, 172–179.